Roadmap to drugs.
In the pharmaceutical group, after the recent correction, we see a new wave of demand in most symbols. The drugs are once again on the path of increasing rates and it seems that the increasing trend in drugs will continue until the arrival of the monthly reports. In the future, any company that sees a green light in the November report will continue to grow, and the price correction will take place in companies with weak reports.